

About Acetyl-L-Carnitine
Acetyl-L-carnitine (ALC) is a biochemical substance made by all organisms except bacteria. Every cell of every plant, animal,
yeast, mold, mushroom, and protozoan makes acetyl-L-carnitine molecules and uses them in the extraction of energy from fats.
In the body, ALC and L-carnitine are interconvertible.
ALC’s essential role in fat metabolism
Cells are constantly breaking down fat molecules and making new ones. This is how cells
- maintain and repair their internal and external membranes;
- adjust the structure of these membranes in response to changing conditions;
- take advantage of the energy contained in dietary fats.
A fat molecule typically consists of three fatty acids bonded to a glycerol bridge. The process of breaking down fats starts
with enzymes that pull the fatty acids off of their glycerol bridges. The free fatty acids are then sent to subcellular organelles
called ‘mitochondria’ for further processing.
Mitochondria, however, are bounded by a protective barrier — a double membrane that prevents inappropriate molecules from
entering and disrupting the specialized processes that take place inside. Even appropriate molecules may require assistance in passing through this barrier. In particular, many of our dietary fatty acids (the longer-chain
ones) are unable to enter a mitochondrion in their free form.
To enable long-chain fatty acids to pass through this barrier, cells ‘tag’ them with a carrier substance called ‘L-carnitine’
— an enzyme attaches a molecule of L-carnitine to each fatty acid. A transporter protein in the inner membrane will now recognize
the carnitine-fatty-acid construct and allow it to pass through the membrane into the interior of the mitochondrion.
Once a fatty acid molecule is inside the mitochondrion, its L-carnitine tag is stripped off and the fatty acid is taken up
by a processing complex that breaks it into small pieces, exposes the pieces to oxygen atoms, and siphons off the energy released
during the resulting chemical reactions, storing it for future use.
What happens to the L-carnitine tags? Some of them are directly transported back out through the mitochondrial membranes into
the cell-at-large; these are now ready to transport more fatty acid molecules into the mitochondria. Others of the L-carnitine
molecules are converted to acetyl-L-carnitine which is efficiently ferried out of the mitochondria by membrane proteins. Thus,
acetic acid molecules use L-carnitine to ‘hitch a ride’ out of the mitochondria so that they can be used in the many ‘acetylation’
processes that take place in cells. Once outside the mitochondria, acetyl-L-carnitine can be deacetylated back to L-carnitine for reuse as a fatty acid transporter.
What we can’t tell you
In the U.S. and some other industrialized countries, government agencies like the U.S. Food and Drug Administration have adopted
censorship as a method for intensifying their control over the supplement industry and its customers. Thus, FDA regulations
prohibit us from telling you that any of our products are effective as medical treatments, even if they are, in fact, effective.
Accordingly, we will limit our discussion of acetyl-L-carnitine to a brief summary of relevant research, and let you draw
your own conclusions about what medical conditions it may be effective in treating.
ALC as a treatment for aging: the theory behind it
‘Aging’ is a catch-all term that covers many different medical ailments — weakening bones, muscles, and skin; stiffening blood
vessels and connective tissue; failing memory, cognition, and sensory organs; loss of cancer suppression; etc. Thousands of
medical names have been given to different variations of these ailments — names such as ‘osteoporosis, arthritis, Alzheimer’s,
atherosclerosis, pancreatic cancer, macular degeneration, etc. But these age-related ailments share some fundamental causes,
such as:
- structural damage by free radicals inside and outside of cells
- protein damage from cross-linking sugars
- growing numbers of incorrectly regulated genes
- skewed proportions of molecules in biological membranes
- biochemical feedback loops that stray from stable patterns.
These (and several other fundamental causes of aging) take place throughout the body, and they affect all the structures inside
and outside the cells. Among the structures they affect are the mitochondria — the subcellular organelles that extract energy
from fats and carbohydrates. As mitochondria extract energy from these substances, they store the energy in the form of ATP
molecules, which are distributed to all parts of all cells in the body.
As cells age, their mitochondria age. The mitochondrial membranes develop skewed proportions of the various molecules they
are made of — particularly the lipid molecules which are made from fatty acids. This disrupts the functions of complex nanomachinery
which resides in the membranes. Some of these nanomachines transport molecules into and out of the mitochondria; others perform
the actual extraction of energy from broken-down fats and carbohydrates, and channel this energy into the production of molecules
of ATP.
Thus, a skewed membrane composition causes disrupted nanomachine function, which leads to a defective transport of raw materials
and to a decline in ATP production. As the transport system fails and the wrong kinds of molecules are allowed into the mitochondria,
the composition of the membranes becomes even more skewed. The energy-extracting nanomachines are forced into non-optimal
positions in the membranes and they become less efficient; an increasing percentage of the energy they produce is wasted instead
of being stored; and the mitochondria, and the cells they belong to, become starved for energy. The wasted energy is simply
dissipated as heat instead of being used for maintaining biological structures and for enabling damaged cells to be replaced.
The current view is that ALC supplementation increases the amount of L-carnitine available for tagging fatty acids in cells.
This, in turn, alters the distribution of fatty acids transported into mitochondria. A better fatty acid mix restores the
proper proportions of lipid molecules in the mitochondrial membranes. With an improved membrane environment, the nanomachines
embedded in the membranes perform better. As a result, the efficiency of energy production in mitochondria is enhanced, enabling
more of the energy extracted from food to be stored as ATP instead of being wasted as heat. The subject is too complex to
describe here in more detail than this, but the ‘bottom line’ is that ALC rejuvenates mitochondria, and the boost in useful
energy that results from this enables cells to behave more youthfully, too.
Potential uses of ALC
Since ALC plays a central role in the production of energy in cells of all kinds, an increase in ALC availability would be
expected to ameliorate many different kinds of ailments that involve cellular energy deficiency or impaired fat metabolism.
Athletic individuals could reasonably expect that ALC consumption would lead to accelerated fat metabolism and increased endurance
during exercise.
But ALC also has effects that seem to be independent of its involvement in energy production. For example, ALC enhances the
production of the neurotransmitter acetylcholine, it stimulates the synthesis of protein, and it affects the fluidity of biological
membranes. The mechanisms are poorly understood, but we can nevertheless exploit them to alter the performance of our bodies
and minds.
Medical conditions which have responded well to ALC supplements include:
- Alzheimer’s, Parkinson’s, and other neurodegenerative diseases
- Hepatic neuropathy and encephalopathy
- macular degeneration
- HIV-related lipodystrophy
- increased fat metabolism and endurance during exercise
- diabetes and diabetic neuropathy
- Peripheral neuropathy due to HIV or cancer chemotherapy
- high blood pressure
- recovery from heart attacks
- recovery from strokes
- age-related memory decline
- low libido and erectile dysfunction
- MS-related fatigue
- noise-induced hearing loss
- Peyronie’s disease
- Rett syndrome cardiac failure
- Nerve injury
- Peripheral neuropathy
- fibromyalgia
- eye-lens stiffening
- depression
Several of these ALC applications have been receiving much attention recently. Let’s look briefly at these.
Alzheimer’s and Parkinson’s
The first clinical study of ALC for treating Alzheimer’s Disease was reported in 1983. Wouldn’t you think that by now, a quarter of a century later, the medical world would have settled the question of whether
or not this substance should be a standard weapon against this disease? Well, it hasn’t, for reasons that are controversial.
Cynics claim that the medical profession downplays all dietary supplements because physicians are being bribed by the makers
of prescription drugs. Others claim that mainstream medicine shies away from supplements because they give inconsistent results
in human clinical trials — and that these trials of supplements are conducted sloppily, on low budgets, in contrast to prescription
drugs, which are tested in high-budget trials.
Be that as it may, many studies of ALC in cell culture, lab animals, and in humans have demonstrated unequivocal anti-Alzheimer’s
effects. As summarized in one medical review, “improvements were noted in spatial learning tasks, timed tasks of attention,
discrimination-learning tasks, and tasks of personal recognition.”
Several mechanisms have been suggested through which ALC produces its anti-Alzheimer’s effects. These include anti-oxidant
action, prevention of apoptosis (cell-death by caused by signalling molecules), and prevention of toxicity due to amyloid proteins.
ALC has received attention from Parkinson’s researchers, too. The beneficial action of ALC in Parkinson’s Disease has been shown both in animal models and in humans. The mechanisms suggested by researchers to explain the anti-Parkson’s effects are vague and involve preventing oxidative
damage.
Brain rejuvenation and nerve repair
ALC enhances the effects of the Nerve Growth Factor — a substance made in the nervous system that stimulates nerve growth.
Tissue culture and lab animal experiments show that ALC causes heightened production of the receptor with which nerve cells
detect and respond to Nerve Growth Factor. This results in faster repair of damaged nerve cells and the replacement of brain neurons that have been lost through trauma or aging.
Blood pressure and heart protection
Two potential cardiovascular benefits of ALC supplementation were recently shown in clinical studies. First, a significant
lowering of blood pressure was seen in patients with coronary artery disease who were given combination of ALC with alpha-lipoic
acid for 8 weeks. And second, it was found that heart attacks will cause less damage to the heart if the subjects (lab animals, in these studies)
have been treated with ALC a few hours prior to the attacks.
Bioavailability
It is often stated by promoters of acetyl-L-carnitine that, for use as a supplement, this form of carnitine is superior to
L-carnitine itself because it has a higher bioavailability. However, the absolute oral bioavailability of acetyl-L-carnitine
has not been determined in humans. It may well be higher than that of L-carnitine (which varies dramatically and inversely
with dosage). Regardless of what the percentage bioavailability of ALC turns out to be, it does what we want it to do: it raises blood
concentrations of ALC, making more of it available to cells throughout the body. In fact, 2 g/day of an oral ALC supplement
will increase blood levels to 143% of the pre-dose value.
Furthermore, ALC readily crosses the blood-brain-barrier. Its measurable effects on energy production and on neurotransmitter production in nerve cells have inspired numerous studies
of its ability to reverse the mental symptoms of aging and neurodegenerative diseases.
Dosages and co-supplements
Oral dosages of 1-3 g/day have been used in clinical trials for the medical conditions for which ALC has been studied. In
Alzheimer’s studies, for example, a typical dosage would be 500 mg taken three times per day. Much higher doses have been studied informally as an anti-aging treatment, with no apparent ill effects.
Since acetyl-L-carnitine enhances mitochondrial energy production, and since destructive free radicals are always a by-product
of this process, it is important to scavenge these free radicals before they can damage the mitochondria and other cellular
structures. The standard way to accomplish this scavenging is to use a second supplement — the antioxidant alpha-lipoic acid. A reasonable dosage would be 100 mg of alpha-lipoic acid three times per day.
Anyone who is considering the use of ALC for treating or preventing Alzheimer’s, Parkinson’s, or other neurodegenerative disease,
should also consider the simultaneous use of a curcumin-containing product like LifeLink’s Primeric™. The mechanism of action
of curcumin is unrelated to that of ALC, which means that the combination may benefit from synergism.
Conclusion
Are acetyl-L-carnitine supplements useful for the conditions and purposes mentioned above? We aren’t allowed to tell you,
so you should take a look at some of the references cited here, and then decide for yourself.
References
[1]
Peripheral neuropathy: pathogenic mechanisms and alternative therapies.
Altern Med Rev. 2006 Dec; 11(4):294-329
Head KA
[2]
Acetyl-L-carnitine.
Altern Med Rev. 1999 Dec; 4(6):438-41
[3]
Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease.
Int J Clin Pharmacol Res. 1990; 10(1-2):139-43
Puca FM, Genco S, Specchio LM, Brancasi B, D'Ursi R, Prudenzano A, Miccoli A, Scarcia R, Martino R, Savarese M
[4]
Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial.
Dig Dis Sci. 2006 Dec; 51(12):2242-7
Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, Rampello L
[5]
Effects of a single, short intravenous dose of acetyl-L-carnitine on pattern-reversal visual-evoked potentials in cirrhotic
patients with hepatic encephalopathy.
Clin Exp Pharmacol Physiol. 2006 Nov; 33(1-2):76-80
Siciliano M, Annicchiarico BE, Lucchese F, Bombardieri G
[6]
Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination
of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10.
Ophthalmologica. 2005 May-Jun; 219(3):154-66
Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C
[7]
Acetyl-L-carnitine for the treatment of HIV lipoatrophy.
Ann N Y Acad Sci. 2004 Nov; 1033:139-46
Day L, Shikuma C, Gerschenson M
[8]
New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle.
J Physiol. 2007 Jun 1; 581(Pt 2):431-44
Stephens FB, Constantin-Teodosiu D, Greenhaff PL
[9]
Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients.
Metabolism. 2000 Jun; 49(6):704-8
Giancaterini A, De Gaetano A, Mingrone G, Gniuli D, Liverani E, Capristo E, Greco AV
[10]
Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled
study.
Drugs R D. 2002; 3(4):223-31
De Grandis D, Minardi C
[11]
Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy.
HIV Clin Trials. 2005 Nov-Dec; 6(6):344-50
Herzmann C, Johnson MA, Youle M
[12]
Effect of acute administration of L-acetyl carnitine on cerebral blood flow in patients with chronic cerebral infarct.
Pharmacol Res. 1991 Apr; 23(3):241-6
Postiglione A, Soricelli A, Cicerano U, Mansi L, De Chiara S, Gallotta G, Schettini G, Salvatore M
[13]
Acetyl-L-carnitine and α-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests.
FASEB J. 2007 Jul 10;
Milgram NW, Araujo JA, Hagen TM, Treadwell BV, Ames BN
[14]
A review of nutrients and botanicals in the integrative management of cognitive dysfunction.
Altern Med Rev. 1999 Jun; 4(3):144-61
Kidd PM
[15]
Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with
male aging.
Urology. 2004 Apr; 63(4):641-6
Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G
[16]
Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results
of a pilot, randomised, double-blind, crossover trial.
J Neurol Sci. 2004 Mar 15; 218(1-2):103-8
Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C
[17]
Prevention of impulse noise-induced hearing loss with antioxidants.
Acta Otolaryngol. 2005 Mar; 125(3):235-43
Kopke R, Bielefeld E, Liu J, Zheng J, Jackson R, Henderson D, Coleman JK
[18]
Pharmacological rescue of noise induced hearing loss using N-acetylcysteine and acetyl-L-carnitine.
Hear Res. 2007 Apr; 226(1-2):104-13
Coleman JK, Kopke RD, Liu J, Ge X, Harper EA, Jones GE, Cater TL, Jackson RL
[19]
Towards an evidence-based understanding of Peyronie's disease.
Int J STD AIDS. 2005 Mar; 16(3):187-94; quiz 94-5
Cavallini G
[20]
Effects of acetyl-L-carnitine on cardiac dysautonomia in Rett syndrome: prevention of sudden death?
Pediatr Cardiol. 2006 Mar; 26(5):574-7
Guideri F, Acampa M, Hayek Y, Zappella M
[21]
Delayed acetyl-L-carnitine administration and its effect on sensory neuronal rescue after peripheral nerve injury.
J Plast Reconstr Aesthet Surg. 2007; 60(2):114-8
Wilson AD, Hart A, Brännström T, Wiberg M, Terenghi G
[22]
Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients.
Clin Exp Rheumatol. 25(2):182-8
Rossini M, Di Munno O, Valentini G, Bianchi G, Biasi G, Cacace E, Malesci D, La Montagna G, Viapiana O, Adami S
[23]
Acetyl- L -carnitine decreases glycation of lens proteins: in vitro studies.
Exp Eye Res. 1999 Jul; 69(1):109-15
Swamy-Mruthinti S, Carter AL
[24]
A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia.
Eur Neuropsychopharmacol. 2006 May; 16(4):281-7
Zanardi R, Smeraldi E
[25]
[The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results]
Clin Ter. 1983 Apr 30; 105(2):135-45
Acierno G
[26]
Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated
oxidative stress and neurotoxicity: implications for Alzheimer's disease.
J Neurosci Res. 2006 Aug 1; 84(2):398-408
Abdul HM, Calabrese V, Calvani M, Butterfield DA
[27]
Folate, vitamin E, and acetyl-L-carnitine provide synergistic protection against oxidative stress resulting from exposure
of human neuroblastoma cells to amyloid-beta.
Brain Res. 2005 Nov 9; 1061(2):114-7
Dhitavat S, Ortiz D, Rogers E, Rivera E, Shea TB
[28]
Bioenergetic approaches for neuroprotection in Parkinson's disease.
Ann Neurol. 2003; 53 Suppl 3:S39-47; discussion S47-8
Beal MF
[29]
Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding
using integrative management.
Altern Med Rev. 2005 Dec; 10(4):268-93
Kidd PM
[30]
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates.
J Neural Transm Park Dis Dement Sect. 1991; 3(1):63-72
Bodis-Wollner I, Chung E, Ghilardi MF, Glover A, Onofrj M, Pasik P, Samson Y
[31]
Levocarnitine acetyl stimulates peripheral nerve regeneration and neuromuscular junction remodelling following sciatic nerve
injury.
Int J Clin Pharmacol Res. 1992; 12(5-6):269-79
De Angelis C, Scarfò C, Falcinelli M, Reda E, Ramacci MT, Angelucci L
[32]
Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous
system of aged rats.
Exp Gerontol. 1994 Jan-Feb; 29(1):55-66
Taglialatela G, Navarra D, Cruciani R, Ramacci MT, Alemà GS, Angelucci L
[33]
Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution
in healthy adult male volunteers.
J Pharm Sci. 1995 May; 84(5):627-33
Sahajwalla CG, Helton ED, Purich ED, Hoppel CL, Cabana BE
[34]
Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism.
Ann N Y Acad Sci. 2004 Nov; 1033:30-41
Rebouche CJ
[35]
Acetyl-L-carnitine in Alzheimer disease: a short-term study on CSF neurotransmitters and neuropeptides.
Alzheimer Dis Assoc Disord. 1995; 9(3):128-31
Bruno G, Scaccianoce S, Bonamini M, Patacchioli FR, Cesarino F, Grassini P, Sorrentino E, Angelucci L, Lenzi GL
[36]
Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer
type.
Eur J Clin Pharmacol. 1992; 42(1):89-93
Parnetti L, Gaiti A, Mecocci P, Cadini D, Senin U
[37]
Role of carnitine esters in brain neuropathology.
Mol Aspects Med. 2004 Oct-Dec; 25(5-6):533-49
Virmani A, Binienda Z
[38]
Oxidative damage and mitochondrial decay in aging.
Proc Natl Acad Sci U S A. 1994 Nov 8; 91(23):10771-8
Shigenaga MK, Hagen TM, Ames BN
[39]
ALC+ALA: One month of “rejuvenation”
Delano Report website; 2003 Nov
Mills R
[40]
Alpha-Lipoic Acid and Acetyl-L-Carnitine: New evidence for rejuvenation potential
Delano Report website; 2002 Feb
[41]
Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients
with coronary artery disease.
J Clin Hypertens (Greenwich). 2007 Apr; 9(4):249-55
McMackin CJ, Widlansky ME, Hamburg NM, Huang AL, Weller S, Holbrook M, Gokce N, Hagen TM, Keaney JF, Vita JA
[42]
Reversal of mitochondrial defects before ischemia protects the aged heart.
FASEB J. 2006 Jul; 20(9):1543-5
Lesnefsky EJ, He D, Moghaddas S, Hoppel CL
